Skip to main content
. 2018 Nov 7;4(11):eaau0731. doi: 10.1126/sciadv.aau0731

Fig. 2. Ponatinib blocks MEKK3-induced signaling in endothelial cells.

Fig. 2

(A to F) Gene expression analysis of ponatinib-treated HUVECs with siRNA-induced CCM1 (si-CCM1) gene knockdown. Ponatinib treatment in HUVECs normalized the increased expression of KLF2 (A), eNOS (B), and AQP1 (C), as well as ADAMTS1 (D), ADAMTS4 (E), and ADAMTS9 (F), following CCM1 knockdown. (G to H) Western blotting analysis showing that ponatinib treatment decreased KLF2, eNOS, ADAMTS1, and ADAMTS4 expression. (I) Ponatinib treatment decreased the expression levels of ERK5 and p-ERK5. Error bars shown as SEM and significance determined by one-way analysis of variance (ANOVA) for multiple comparisons (n = 4). “*” indicates P < 0.05, “**” indicates P < 0.001, and n.s. indicates P > 0.05. Western blotting images are representatives of three independent experiments. The quantification of relative density ratios is shown underneath each blot.